Novartis AG
NOVN#37 of 134 by buybacksSW · Healthcare · Drug Manufacturers - General · Switzerland
novartis.comBuybacks · TTM to Jun 2026$6.76Blatest four quarters
Buyback yield2.5%repurchases ÷ market cap
Dividends · TTM to Jun 2026$9.22Bdividend yield 3.4%
Shareholder yield5.9%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−15.0%1.91B shares (2026)
Buybacks ÷ free cash flow42%payout incl. dividends 100%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $9.65B | $8.19B | $18.4B |
| FY2024Dec 2024 | $8.33B | $7.62B | $13.8B |
| FY2023Dec 2023 | $8.72B | $7.25B | $11.7B |
| FY2022Dec 2022 | $10.7B | $7.51B | $11.6B |
| FY2021Dec 2021 | $3.06B | $7.37B | $12.1B |
| FY2020Dec 2020 | $2.84B | $6.99B | $11.1B |
| FY2019Dec 2019 | $5.53B | $6.64B | $11.4B |
Repurchases in FY2025 were +15.8% versus the prior year.
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revo…
- Market cap
- CHF 226B
- P/E (trailing)
- 22.4×
- Fiscal year end
- December
- ISIN
- CH0012005267
- Reporting currency
- USD
- Data updated
- Oct 9, 2026